Follicular Lymphoma
A phase II trial found antitumor effect across patient subgroups and independently of risk factors for disease progression.
Treatment with liso-cel was effective and safe in patients with relapsed or refractory follicular lymphoma in TRANSCEND FL.
Lenalidomide, rituximab, and ibrutinib was effective as a first-line therapy for patients with follicular lymphoma and MZL.
Advertisement
Around two-thirds of patients with follicular lymphoma receive at least two lines of therapy during their lifetime.
The Committee for Medicinal Products for Human Use of the European Medicines Agency supported approving zanubrutinib for FL.
The CAR T-cell therapy received accelerated approval for adults with R/R FL after two or more lines of systemic therapy.
Advertisement
The European Commission has approved the chimeric antigen receptor (CAR) T-cell therapy tisagenlecleucel for the treatment of ...
The phase III GALLIUM study confirmed obinutuzumab plus chemotherapy as a standard of care for first-line follicular lymphoma
The U.S. Food and Drug Administration (FDA) has granted tisagenlecleucel accelerated approval for adult patients with ...
The results did not provide any clear benefit by adding venetoclax in patients with previously untreated follicular lymphoma.
The CAR T-cell therapy was approved for adult follicular lymphoma patients who have received two or more lines of systemic ...
After failing to complete the requisite confirmatory trials following accelerated approval, Gilead has announced it will ...
Research indicates that Hispanic patients with DLBCL have better survival than non-Hispanic White.
630 Madison Ave.
Manalapan, NJ 07726
© 2025 Mashup Media, LLC, a Formedics Property. All Rights Reserved.